Results 91 to 100 of about 20,675,763 (300)

Cost-Utility Analysis of Rosuvastatin (20 mg) to Prevent Cardiovascular Diseases in Iran

open access: yesAdvanced Biomedical Research
Background: Cardiovascular diseases are a main cause of disease burden in developing and developed countries. This study aimed to evaluate the cost-utility of rosuvastatin 20 mg in contrast with no intervention for the prevention of cardiovascular ...
Aziz Rezapour   +2 more
doaj   +1 more source

Economic evaluation of an extended nutritional intervention in older Australian hospitalized patients: a randomized controlled trial

open access: yesBMC Geriatrics, 2018
Background Prevalence of malnutrition in older hospitalized patients is 30%. Malnutrition is associated with poor clinical outcomes in terms of high morbidity and mortality and is costly for hospitals.
Yogesh Sharma   +6 more
doaj   +1 more source

Disability-adjusted life years (DALYs) based COVID-19 health impact assessment: A systematic review

open access: yes, 2023
Background The emergence of COVID-19 has resulted in health, socio-economic, and political crises. The overall health impact of this disease can be measured by disability-adjusted life years (DALYs) which is the sum of the life years lost due to ...
Islam, Md Shahidul   +7 more
core   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

open access: yesMolecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler   +3 more
wiley   +1 more source

Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation

open access: yesHealth Technology Assessment, 2020
Background: Splints are a non-invasive, reversible management option for temporomandibular disorders or bruxism. The clinical effectiveness and cost-effectiveness of splints remain uncertain.
Philip Riley   +8 more
doaj   +1 more source

The projected changes in quality adjusted life years lost related to COPD in Canada in men (A) and women (B).

open access: yes, 2012
The projected changes in quality adjusted life years lost related to COPD in Canada in men (A) and women (B).
Larry D. Lynd (115952)   +6 more
core   +1 more source

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso   +5 more
wiley   +1 more source

Medical costs and quality-adjusted life years associated with smoking: a systematic review

open access: yesBMC Public Health, 2016
Background Estimated medical costs (“T”) and QALYs (“Q”) associated with smoking are frequently used in cost-utility analyses of tobacco control interventions.
Shari P. Feirman   +6 more
doaj   +1 more source

Cost-utility model input parameters: Principal event probabilities, lifetime costs and quality-adjusted life years.

open access: yes
Cost-utility model input parameters: Principal event probabilities, lifetime costs and quality-adjusted life years.
Dyfrig Hughes (40543)   +5 more
core   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy